Advances in AAV vector development for gene therapy in the retina

Area of Science:

• Ophthalmology
• Gene Therapy
• Virology

Background:

• Adeno-associated virus (AAV) is a non-pathogenic virus with potential for safe, long-term genetic payload expression in the retina.
• AAV is utilized in animal models for inherited retinal degeneration, but faces limitations such as restricted carrying capacity and inefficient transduction of certain retinal cells.

Purpose of the Study:

• To address the limitations of current Adeno-associated virus (AAV) vectors for treating inherited retinal diseases.
• To explore advancements in AAV vector technology for improved therapeutic applications.

Main Methods:

• Development of next-generation AAV vectors through rational design, including self-complementary AAV vectors for rapid expression.
• Utilizing directed evolution to create novel AAV variants with enhanced characteristics via iterative selection.
• Engineering AAV surface residues to improve viral particle transduction efficiency.

Main Results:

• Novel AAV variants generated through directed evolution demonstrate improved therapeutic potential.
• Rational design approaches, like self-complementary vectors, aim to accelerate gene expression onset.
• Modifications to AAV surface residues enhance viral transduction capabilities.

Conclusions:

• Next-generation AAV vectors, developed through rational design and directed evolution, offer improved therapeutic potential for inherited retinal degeneration.
• Further advancements in AAV vector technology promise broader applicability and enhanced treatments for inherited eye diseases.
• Combining rational design and directed evolution may yield superior AAV variants for retinal gene therapy.